Vanda Pharmaceuticals Inc. (FRA:VM4)
Germany · Delayed Price · Currency is EUR | Market Cap | 375.05M +48.7% |
| Revenue (ttm) | 180.75M +11.1% |
| Net Income | -71.76M |
| EPS | -1.23 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Average Volume | 106 |
| Open | 6.60 |
| Previous Close | 6.40 |
| Day's Range | 6.60 - 6.60 |
| 52-Week Range | 3.46 - 7.60 |
| Beta | n/a |
| RSI | 53.45 |
| Earnings Date | Feb 12, 2026 |
About Vanda Pharmaceuticals
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson’s disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Ponvory for the treatment of psoriasis and ulcerative colitis. Its pipeline products include HETLIOZ (tasimelteon) ... [Read more]
News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA
NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Vanda Pharmaceuticals Inc. (“Vanda” or the “Company”) (NASDAQ: VNDA). Such investors are a...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA
NEW YORK, Jan. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") (NASDAQ: VNDA). Such investors are advised...
Millennium Management LLC Reduces Stake in Vanda Pharmaceuticals Inc
Millennium Management LLC Reduces Stake in Vanda Pharmaceuticals Inc
Vanda Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript
Vanda Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript
Vanda Pharmaceuticals Inc. (VNDA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Vanda Pharmaceuticals Inc. (VNDA) 44th Annual J.P.
Lost Money on Vanda Pharmaceuticals Inc. (VNDA)? Contact Levi & Korsinsky About Fraud Investigation
New York, New York--(Newsfile Corp. - January 15, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Vanda Pharmaceuticals Inc. ("Vanda Pharmaceuticals Inc.") (NAS...
Lost Money on Vanda Pharmaceuticals Inc. (VNDA)? Contact Levi & Korsinsky About Fraud Investigation
New York, New York--(Newsfile Corp. - January 15, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Vanda Pharmaceuticals Inc. ("Vanda Pharmaceuticals Inc.") (NAS...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA
NEW YORK, Jan. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") (NASDAQ: VNDA). Such investors are advise...
Vanda Pharmaceuticals (VNDA) Faces FDA Setback on HETLIOZ Application
Vanda Pharmaceuticals (VNDA) Faces FDA Setback on HETLIOZ Application
Vanda and Exante Data Combine in Strategic Merger
LONDON & NEW YORK--(BUSINESS WIRE)--This morning Vanda, a global leader of high-frequency positioning data and tactical macro insights and Exante Data Inc, an innovative data analytics and global macr...
Vanda Pharmaceuticals (VNDA) Faces Setback with FDA Rejection
Vanda Pharmaceuticals (VNDA) Faces Setback with FDA Rejection
Why Is Vanda Pharmaceuticals Stock Falling In Pre-market?
(RTTNews) - Vanda Pharmaceuticals (VNDA) said it has received a decision letter from the FDA Center for Drug Evaluation and Research concluding that the supplemental New Drug Application for HETLIOZ f...
Vanda Pharmaceuticals (VNDA) Shares Fall After FDA Decision
Vanda Pharmaceuticals (VNDA) Shares Fall After FDA Decision
Vanda Pharmaceuticals Announces Receipt of FDA Decision Letter on HETLIOZ® Supplemental New Drug Application for Jet Lag Disorder
WASHINGTON, Jan. 8, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that it has received a decision letter from the U.S. Food and Drug Administration's (FDA) Cen...
FDA Approves Vanda Pharma Motion Sickness Drug, Fuels Upside
In December, the U.S. Food and Drug Administration (FDA) approved Vanda Pharmaceuticals Inc. ‘s (NASDAQ: VNDA) Nereus (tradipitant) to prevent vomiting induced by motion . The approval marks the firs...
Vanda Pharmaceuticals: SG&A Takes Off, TAM Doesn't (Rating Downgrade)
Vanda's 2026 Catalyst Run With Nereus Launch And Bysanti PDUFA In Focus
Vanda Pharmaceuticals is buy-rated following FDA approval of Nereus for motion sickness, with shares offering upside into 2026 catalysts. VNDA's Q3 saw strong Fanapt sales growth, but higher R&D and S...
What's Going On With Vanda Pharmaceuticals Stock Wednesday?
Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) shares are trading higher Wednesday after the company announced it received FDA approval of NEREUS for the prevention of vomiting induced by motion . Vanda P...
Vanda Pharmaceuticals Stock Surges 29% After FDA Clears Motion Sickness Drug
(RTTNews) - Vanda Pharmaceuticals Inc. (VNDA) shares jumped 29.13%, trading at $9.08, up $2.05, after the company announced that the U.S. Food and Drug Administration approved NEREUS (tradipitant) for...
Why FuelCell Energy Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of FuelCell Energy, Inc. (NASDAQ: FCEL) fell sharply during Wednesday's session after the company filed for an amended common stock offering . After market close on Tuesday, FuelCell said in a...
Vanda Pharmaceuticals Shares Jump 30% on Motion Sickness Drug Approval
The FDA approved Vanda's drug Nereus to prevent motion-induced vomiting, opening a potential path into treating nausea linked to GLP-1 weight-loss drugs.
Vanda Pharmaceuticals (VNDA) Surges 21% on FDA Approval of Motion Sickness Drug
Vanda Pharmaceuticals (VNDA) Surges 21% on FDA Approval of Motion Sickness Drug
Vanda Pharmaceuticals (VNDA) Gains FDA Nod for Motion Sickness Drug
Vanda Pharmaceuticals (VNDA) Gains FDA Nod for Motion Sickness Drug
Vanda surges on FDA approval of Lilly-partnered motion sickness therapy
Vanda Pharmaceuticals (VNDA) stock rises as the FDA approves its motion sickness therapy Nereus, developed in partnership with Eli Lilly (LLY). Read more here.
Why Vanda Pharmaceuticals Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
Shares of Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) rose sharply in pre-market after the company announced U.S. Food and Drug Administration approval of NEREUS (tradipitant), an oral neurokinin-1 rec...